Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (111-120 of 153) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC studyThomas Pierret, Laurent Greillier, Florian Guisier, et al.
Therapeutic Advances in Medical Oncology|March 8, 2024
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III TrialGuillaume Eberst, Amélie Anota, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
British Journal of Cancer|May 3, 2017
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignanciesRastislav Bahleda, Juneko E Grilley-Olson, Ramaswamy Govindan, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Ebiomedicine|May 27, 2023
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerFrançois Ghiringhelli, Frederic Bibeau, Laurent Greillier, et al.
Pageof 16

Showing results (111-120 of 153) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC studyThomas Pierret, Laurent Greillier, Florian Guisier, et al.
Therapeutic Advances in Medical Oncology|March 8, 2024
Resected <i>EGFR</i>-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2019
Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III TrialGuillaume Eberst, Amélie Anota, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 3, 2024
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, et al.
Lung Cancer (Amsterdam, Netherlands)|July 7, 2024
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trialOlivier Bylicki, Florian Guisier, Arnaud Scherpereel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutationJean Bernard Auliac, Maurice Pérol, David Planchard, et al.
Clinical Lung Cancer|September 14, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World AnalysisAntoine Bronstein, Hubert Curcio, Isabelle Monnet, et al.
British Journal of Cancer|May 3, 2017
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignanciesRastislav Bahleda, Juneko E Grilley-Olson, Ramaswamy Govindan, et al.
Cancer Treatment Reviews|March 29, 2025
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?Arthur Géraud, Paul Gougis, Alexandre de Nonneville, et al.
Ebiomedicine|May 27, 2023
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerFrançois Ghiringhelli, Frederic Bibeau, Laurent Greillier, et al.
Pageof 16